On January 5, 2026, Chief Medical Officer Hamilton James C reported the sale of 4,625 shares in a Form 4 filing, reducing his ownership to 207,497 shares. On the same day, Director Mauro Ferrari sold 7,530 shares for a total consideration of 527,100, bringing his remaining stake to 69,053 shares (valued at approximately 4.83 million) and marking a 9.83% reduction in his holdings. Ferrari had previously sold 8,750 shares on November 28, 2025, for a total of 493,412.50, underscoring a pattern of gradual divestment by senior insiders.

Arrowhead’s most recent session opened down 1.3% and closed with a 5.8% decline, erasing gains from earlier in the week. Trading volume reached 2.69 million shares, well above the 50-day average of 1.8 million, indicating heavier turnover. The stock’s 50-day moving average stands at 53.54, up 14% over the past two months, suggesting positive medium-term momentum despite the latest pullback. Over the past 12 months, the share count has traded in a range equivalent to a low of 9.57 and a high of 72.36 on an adjusted basis.

Arrowhead remains a leader in RNA interference therapeutics, targeting intractable diseases by silencing pathogenic genes. Its pipeline includes candidates for liver, metabolic and respiratory disorders. The company competes directly with established RNAi firms such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals, leveraging proprietary delivery platforms to enhance tissue specificity and durability. With a market capitalization near 8.83 billion and strong institutional backing, Arrowhead is positioned to advance multiple late-stage programs through 2026.